Dose Insider / Analyses / Zepbound and birth control

Zepbound and Birth Control PillsThe 4-Week Rule, With Your Dates

Updated November 20, 2026 · 20 min read · FDA labels, two 2026 reviews

Zepbound can make birth-control pills less reliable. The label tells women who take an oral contraceptive to switch to a method that is not swallowed, or to add a barrier method such as condoms, for 4 weeks after the first dose and for 4 weeks after every dose increase. Contraceptives that do not go through the stomach are not affected.

4 weeksof a backup method after the first dose and after every dose increase
Weeks of backup birth controlZepbound label rule on the standard schedule, by target doseTo 5 mg8 weeksTo 7.5 mg12 weeksTo 10 mg16 weeksTo 12.5 mg20 weeksTo 15 mg24 weeksWeeks of backup birthcontrolZepbound label rule on the standard schedule, bytarget doseTo 5 mg8 weeksTo 7.5 mg12 weeksTo 10 mg16 weeksTo 12.5 mg20 weeksTo 15 mg24 weeks

4 weeks after the first dose and after every increase; on the standard schedule they join up.

On this page

The rule is in the FDA prescribing information, in the sections on drug interactions and on contraception.1 On the standard schedule, where the dose rises every 4 weeks, the windows touch each other and become one long stretch: up to 24 weeks for someone heading to 15 mg. The calculator shows your own dates.

The rest of the page covers where the rule comes from, what the study behind it measured, which methods are affected, and what the labels say about pregnancy, planning a pregnancy and breastfeeding.

In which weeks do I need a backup method?

Enter the date of your first Zepbound dose, the maintenance dose you are heading for and how long you stay on each step. The shaded stretches are the label's backup windows.

Your backup windowsLabel 7.2, 8.3
Maintenance dose you are heading for
Weeks on each dose after 2.5 mg
Backup ends—
Backup in total—
Backup windowDose

    The app marks each window on your calendar when you log a dose increase.

    Open the app

    The numbers along the bottom are weeks of treatment. Dates follow the label's wording; your own dose changes may fall on other days. This is not contraceptive advice.

    The pattern depends on how fast the dose climbs. At the fastest pace the label allows, every 4-week window ends on the day the next one begins, so the backup period runs without a gap from the first injection until 4 weeks after the last increase. A slower climb breaks it into separate months with clear weeks in between.

    Heading forDose changesBackup at 4 weeks per stepEnds in week
    5 mgstart, then 1 increase8 weeks in a row8
    10 mgstart, then 3 increases16 weeks in a row16
    15 mgstart, then 5 increases24 weeks in a row24

    A worked count

    Take a first dose on Monday, January 4. The first window runs from that day through Sunday, January 31. On February 1 the dose goes to 5 mg and a second window opens, through February 28. If you stay on 5 mg, that is the end: 8 weeks, and nothing further is asked. If you go to 7.5 mg on March 1, a third window runs through March 28.

    Now suppose you stay on 5 mg until May 3 and only then move to 7.5 mg. March and April are clear. A new window opens on May 3 and closes on May 30. The total is the same 12 weeks as before, split into two stretches with nine clear weeks between them. Count 28 days from the date of the first dose at each new strength, and the last day of the window is day 28.

    How many weeks each plan adds up to

    Every strength on the way to your maintenance dose opens one window, the starting 2.5 mg included. The total therefore depends only on how high the dose goes.

    Maintenance doseWindowsWeeks of backupLast window ends, fastest pace
    5 mg28week 8
    7.5 mg312week 12
    10 mg416week 16
    12.5 mg520week 20
    15 mg624week 24

    Our count from the label rule: 4 weeks per strength. The fastest pace is an increase every 4 weeks.

    The pace changes how those weeks are arranged, not how many there are. At the fastest pace the windows run into each other, and someone going to 15 mg needs a backup method for 24 weeks without a break, close to half a year. At a slower pace the same 24 weeks are split into stretches with clear weeks between them. For a course that long, the label's other option, a method that is not taken by mouth, removes the counting altogether.

    What exactly does the label say?

    The instruction appears twice, in nearly the same words. In the section on drug interactions: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected."1

    The section on reproductive potential gives the reason in one sentence: "Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time."

    Three things follow from the wording. The rule is about pills, meaning any hormonal contraceptive that is swallowed. It offers two ways to comply: change the method, or keep the pill and add a barrier. And it is tied to moments of change. Once 4 weeks have passed since the last increase and the dose is steady, the label asks for nothing more.

    Why would an injection affect a pill?

    Through the stomach. A pill has to leave the stomach and reach the small intestine before most of it is absorbed. Zepbound slows the emptying of the stomach, so a pill taken as usual arrives later and is absorbed more slowly. The label describes the stomach effect as strongest at the start: it "was greatest after a single dose of 5 mg and diminished after subsequent doses".1

    That is why the rule has an end. The body adjusts to each dose within weeks, the stomach effect fades, and the label treats the pill as reliable again until the next increase brings a new, smaller disturbance. The same logic explains why a patch, a ring, an implant, an injection or an IUD is untouched: none of them depends on the stomach.

    How fast the stomach effect fades

    The label has a second study that shows the fading directly. It used acetaminophen, a common painkiller, as a tracer for how quickly the stomach empties. After a first 5 mg dose of tirzepatide, the peak level of acetaminophen in the blood was 55% lower and came an hour later. When the test was repeated at week 6, by which time the dose had risen to 15 mg, there was "no meaningful impact" on either number, and the total amount absorbed was unchanged throughout.1

    When the tracer was givenPeak levelTime to peakTotal absorbed
    After the first 5 mg dose55% lower1 hour laterunchanged
    Week 6, on 15 mgno meaningful changeno meaningful changeunchanged

    Six weeks later, on three times the dose, the stomach was handling the tracer normally again. The label puts it in one sentence: the effect on stomach emptying "was greatest after a single dose of 5 mg and diminished after subsequent doses". The body adapts to the drug's effect on the stomach faster than the dose climbs. The 4-week windows are the label's allowance for that adaptation at each step.

    What did the interaction study measure?

    How much pill hormone reached the blood when the pill was taken after a dose of tirzepatide. Participants took a common combined pill, 0.035 mg of ethinyl estradiol with 0.25 mg of norgestimate, after a single 5 mg dose of tirzepatide. The label reports two numbers for each hormone: the peak level and the total amount absorbed.1

    Pill hormones after one dose of tirzepatideFDA label, section 12.3
    Hormone measured

    A single 5 mg dose of tirzepatide, the strongest moment for the stomach effect. Norelgestromin is the form norgestimate takes in the body. The study measured hormone levels. It did not count pregnancies.

    The peak levels fell by 59%, 66% and 55% for the three substances measured, and the peak came 2.5 to 4.5 hours later. The total amount absorbed fell much less: by 20%, 21% and 23%.1 In other words, most of the hormone still got in. It got in late and spread out.

    Whether a drop of about a fifth in total exposure is enough to let ovulation through has not been tested. No study has compared pregnancy rates in pill users with and without tirzepatide. The label takes the cautious reading, and so do the specialist reviews. A 2026 review in the American Journal of Obstetrics and Gynecology concludes that studies of the two drug classes together "are limited" and that "significant knowledge gaps remain", and asks for contraceptive counselling to be routine when one of these drugs is started.3

    The study also looked at the hardest case: a single dose, the moment when the label says the stomach effect is largest. It tells you about the first week of a new dose. It says little about week 10 on a steady one, which is the reasoning behind a rule that switches on and off.

    Which methods are affected, and which are not?

    The dividing line is whether the contraceptive is swallowed.1

    Cheat sheetContraception on Zepbound, by the label
    Sections 7.2 and 8.3
    MethodGoes through the stomach?Label
    Combined pillYesBackup or switch for 4 weeks after starting and after each increase
    Progestin-only pillYesThe same: the rule covers "oral hormonal contraceptives"
    Patch, vaginal ringNo"Should not be affected"
    Injection, implantNo"Should not be affected"
    Hormonal IUDNo"Should not be affected"
    Copper IUD, condomsNo hormones involvedNot affected; condoms are the barrier method the label means
    The windows apply to pills only.doseinsider.com

    The label's two options suit different people. Adding condoms keeps a method you already know and covers the windows as they come. Switching to a method that does not depend on the stomach removes the question for the whole of treatment, which matters most for someone who expects many dose changes, or who would find 24 weeks of doubled methods hard to keep up.

    The label does not mention emergency contraception. The common emergency pills are swallowed, so the same reasoning about absorption would apply to them, and no study has looked. If you need emergency contraception while inside a window, tell the pharmacist or doctor that you take Zepbound and when your dose last changed.

    A switch needs its own check of dates. The UK regulator's guidance for patients adds a caution here: "Not all methods of birth control become effective immediately", and it asks patients to confirm with a healthcare professional or the leaflet of the new method that they are covered.7 If you move from the pill to another method around the time you start Zepbound, ask how many days the new method takes to protect, and keep a barrier method until then.

    Do I need backup once my dose is steady?

    Not under the label. Its windows are attached to two events, starting the drug and raising the dose, and each lasts 4 weeks. A woman who reached 10 mg in March and has stayed there is outside every window from April on. Nothing in the label asks for backup during months on an unchanged dose.

    This also means the total depends on your own path. Someone who settles on 5 mg has two windows and 8 weeks of backup in all. Someone who climbs to 15 mg has six. If you stay on a dose for a while and then go up, a new 4-week window opens on the day of the first higher dose, however long ago the previous one closed.

    What about a lower dose, a missed dose or a restart?

    The label names "initiation" and "dose escalation" and nothing else. A move to a lower dose is not mentioned, and by the logic of the rule it would not open a window, since a smaller dose slows the stomach less than the one the body is used to.

    A restart after a long break is different. Four weeks after the last injection almost none of the drug is left, and the first dose after such a gap meets the body nearly fresh, like a first dose. The label does not define when a restart counts as "initiation". If you have been off for several weeks and are starting again, treating the first 4 weeks as a window is the reading that fits the reason behind the rule. Our page on how long Zepbound stays in the body shows how much is left after any gap.

    A single late or skipped dose does not appear in the contraception sections either. The missed-dose rules are separate.

    Is the rule the same for Mounjaro?

    Yes. Mounjaro is the same drug, tirzepatide, sold for type 2 diabetes, and its label carries the same instruction for oral contraceptives: a non-oral method or an added barrier method for 4 weeks after starting and for 4 weeks after each dose increase.5 Someone who moves from Mounjaro to Zepbound at the same dose has not started anything new as far as the stomach is concerned.

    Do Wegovy and Ozempic have the same rule?

    No. The Wegovy label has no instruction about contraceptive pills. Its interaction section reports that no clinically significant differences were seen in the levels of ethinyl estradiol or levonorgestrel when they were taken with semaglutide.2 It does carry a general caution that a slowed stomach could affect medicines taken by mouth, and asks for their effects to be monitored.

    The difference between the two drugs is one of evidence. For semaglutide a study was done and found no meaningful change. For tirzepatide a study was done and found the changes described above. A 2026 review of the whole class puts it in one sentence: "Most GLP-1 RAs do not significantly affect oral contraceptive pharmacokinetics, although tirzepatide may require temporary backup contraception."4

    Zepbound, MounjaroWegovy
    Drugtirzepatidesemaglutide, as in Ozempic
    Pill study in the labelpeak down 55 to 66%, total down 20 to 23%no clinically significant difference
    Backup rule for pill users4 weeks after starting and after each increasenone
    Before a planned pregnancyno lead time statedstop at least 2 months before

    Professional bodies have begun to write this down for clinicians. In the United Kingdom the Faculty of Sexual and Reproductive Healthcare issued a statement on GLP-1 drugs and oral contraception in February 2025.6

    Does vomiting or diarrhea matter for the pill?

    Yes, and independently of the stomach effect above. A pill that is vomited up soon after it is taken, or that passes through during severe diarrhea, may not be absorbed, whatever caused the upset. Every pill packet has its own instructions for this situation, and they apply on Zepbound as they would with a stomach bug.

    This matters because the weeks in which the label asks for backup are also the weeks in which these side effects are most likely. In the trials, nausea was reported by 25 to 29 in 100 people on Zepbound, vomiting by 8 to 13 and diarrhea by 19 to 23, and the label says most of it "occurred during dose escalation and decreased over time".1 The two risks to the pill overlap in time, which is one more argument for the backup the label asks for.

    What does the label say about pregnancy?

    To stop. "Weight loss offers no benefit to a pregnant patient and may cause fetal harm," the label says, and it tells patients "to discontinue ZEPBOUND when a pregnancy is recognized".1

    It is frank about how little is known. The available data in pregnant women "are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes". The concern rests on animal studies: in rats and rabbits given tirzepatide during pregnancy, the young were smaller, and in rats abnormalities were seen, at exposures similar to those in people. The label notes that these effects went together with reduced food intake and weight in the mothers.

    Two practical points come from the same section. There is a pregnancy registry that follows outcomes in women exposed to the drug, and the label asks pregnant patients and their doctors to contact the maker at 1-800-545-5979. And the label does not ask for routine pregnancy tests during treatment. If your period is late while you are on Zepbound, the usual advice applies: test, and tell your prescriber the result.

    What is known about pregnancies exposed to these drugs

    For tirzepatide, very little: the label says the data are insufficient. For the older drugs of the class there is one large study. Researchers pooled health records from four Nordic countries, the United States and Israel, covering 3.5 million infants, and looked at women with type 2 diabetes who had filled a prescription for a diabetes medicine between 90 days before pregnancy and the end of the first trimester. Among 938 infants exposed to a GLP-1 drug, 8.3% had a major malformation. Among 5,078 exposed to insulin, the drug the study used for comparison, the figure was 7.8%. After adjustment for differences between the mothers, the relative risk for GLP-1 drugs against insulin was 0.95, with a range of 0.72 to 1.26.8

    That result is reassuring as far as it goes, and it does not go to Zepbound. The women had diabetes, which raises the risk of malformations by itself: 5.3% across all infants of mothers with type 2 diabetes against 3.7% in the general population of the study. The births date from 2009 to 2021, before tirzepatide was approved, and the drugs were taken for diabetes. The authors wrote that the results "did not indicate a large increased risk" above the one that comes with the mother's diabetes, called them reassuring, and asked for confirmation from other studies. That is an answer about accidental early exposure to the class. It does not make use in pregnancy safe, and neither the label nor the UK regulator reads it that way.

    How long before trying to conceive should it be stopped?

    The Zepbound label gives no lead time. It speaks only of stopping when a pregnancy is recognized. The Wegovy label is specific for its own drug: "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide".2

    The UK medicines regulator, the MHRA, does give a number for tirzepatide. Its guidance for patients, updated in February 2026, lists how long each drug should be stopped before trying to become pregnant: at least 2 months for semaglutide, at least 1 month for tirzepatide, and none for liraglutide, which the guidance says leaves the body much quicker than the others.7 The same guidance asks women to use contraception while taking these medicines and throughout that wash-out period, and to speak to a healthcare professional straight away if they think they might be pregnant.

    Stop before trying to conceive
    Semaglutide · US label and UK regulatorat least 2 months
    Tirzepatide · UK regulatorat least 1 month
    Tirzepatide · US labelno lead time stated

    The half-life is what makes the question concrete. Tirzepatide has a half-life of 5 to 6 days. After a steady run of weekly doses, about 2% of the usual peak level is left four weeks after the last injection and under 1% after five. Those figures describe the drug level, and the decision about timing belongs with your prescriber, ideally before contraception is stopped.

    There is a second reason to plan. In the trial that tested stopping, weight came back over the following year, and the months of trying to conceive and of pregnancy are months without the drug. That is a conversation about goals as much as about pharmacology, and it goes better before the fact.

    Can Zepbound change periods or fertility?

    The label has no data on either. What exists is early and indirect. A 2026 review of GLP-1 drugs and reproductive health reports that in women with polycystic ovary syndrome these drugs improve insulin resistance and androgen levels "and may improve menstrual regularity". It adds that "evidence regarding fertility outcomes and pregnancy safety remains limited".4

    The practical reading is cautious in one direction. If cycles that were irregular become regular during weight loss, the chance of conceiving may go up at the same moment as the pill becomes less reliable. Nobody has measured how often that leads to an unplanned pregnancy. It is a reason to take the label's windows seriously, and to think about contraception before the first dose and not after a surprise.

    What does the label say about breastfeeding?

    It reports one small study. Eleven healthy breastfeeding women were given a single 5 mg dose, and their milk was sampled afterwards. Tirzepatide was undetectable in 164 of 171 samples, and in the other 7 the amount was low compared with the dose the mother received.1

    The label then states what the study cannot show: "There are no available data on the effects of tirzepatide on the breastfed infant or on milk production." It does not forbid breastfeeding on the drug and does not endorse it. Its wording is that the benefits of breastfeeding should be weighed along with the mother's need for the drug and any possible effect on the child, which is a decision to make with a doctor.

    The UK regulator is stricter on this point than the US label. Its guidance says that GLP-1 medicines "should not be taken by people who are breastfeeding", for the same reason it gives for pregnancy: there is not enough safety data.7 The two positions do not contradict each other. The label reports what was measured and leaves the decision to the doctor and patient. The regulator turns the lack of data into a default.

    Does the rule cover hormone therapy and other pills?

    The 4-week rule is written for "oral hormonal contraceptives" only. Hormone therapy taken by mouth for menopause is not named in the label, and no interaction study with it is reported. What does apply is the label's general statement about medicines taken by mouth: Zepbound "has the potential to impact the absorption" of them, caution is advised, and drugs that depend on a precise level, with warfarin as the example, should be monitored.1

    For a hormone taken as a patch, gel, ring or implant the reasoning about the stomach does not arise. If you take any hormone by mouth and are starting Zepbound, mention it to whoever prescribes it, because the weeks after each dose change are when absorption of a tablet is most likely to shift.

    One more boundary is age. The label states that the safety and effectiveness of Zepbound have not been established in children, so its contraception rule is written with adult patients in mind.

    What should I raise with my prescriber?

    The reviews ask for this conversation to be a routine part of starting treatment, and the label gives it clear content. Four points cover it.

    Whoever prescribes your contraception should know about Zepbound as well. The interaction is listed in the drug's label, and a pharmacist filling both prescriptions can check it in seconds.

    Short answers to common questions

    Does Zepbound cancel out the pill?

    No. In the study most of the hormone was still absorbed: the total fell by about a fifth. The label asks for backup during the 4 weeks after starting and after each dose increase because the reduction may be enough to matter.

    I have an IUD. Does any of this apply to me?

    No. The label says hormonal contraceptives that are not taken by mouth should not be affected.

    Can I take my pill at a different time of day to avoid the interaction?

    The label offers no such option. The stomach effect lasts for days after an injection, so there is no time of day that avoids it.

    My dose went from 5 to 7.5 mg. Is a small increase also a window?

    Yes. The label says "each dose escalation" and makes no exception for step size.

    Is the rule different on Mounjaro?

    No. It is the same drug with the same instruction.

    Do men need to do anything?

    The label's section covers "females and males of reproductive potential", and its only instruction is the one about oral contraceptives.

    I found out I am pregnant while on Zepbound. What now?

    The label says to stop the drug when a pregnancy is recognized and to tell your healthcare provider. It also asks that the maker be contacted for the pregnancy registry.

    Does the rule cover the progestin-only pill?

    Yes, as the label is worded. It speaks of "oral hormonal contraceptives" and makes no exception by type, so a progestin-only pill falls under the same 4-week windows. The study behind the rule tested one combined pill, with 0.035 mg of ethinyl estradiol and 0.25 mg of norgestimate. No progestin-only pill was tested.

    How the calculator works

    The calculator builds the dose schedule from the label: 4 weeks on 2.5 mg, then an increase of 2.5 mg after each period you choose, up to the maintenance dose. It places a 4-week window at the first dose and at every increase, and joins windows that touch. It assumes a pill is your only method. If your own increases happen on other dates, each one starts a window of its own, 4 weeks long.

    The hormone chart shows the figures from the interaction study in section 12.3 of the label as a share of normal: 100% minus the reported reduction. All statements about pregnancy and breastfeeding are quoted from sections 8.1 to 8.3 of the August 2026 revision.

    Sources

    1. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 6.1, 7.2, 8.1, 8.2, 8.3, 12.2 and 12.3. accessdata.fda.gov
    2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 7.2, 8.3 and 12.3. accessdata.fda.gov
    3. Yee HM, Han LL. Contraceptive use and GLP-1 receptor agonists: an intersection of metabolic and reproductive health. Am J Obstet Gynecol 2026. doi:10.1016/j.ajog.2026.10.005
    4. Porterfield F, Mulligan J, Salim K, Olubowale O, Stanford FC. GLP-1 receptor agonists and reproductive health: implications for contraception, fertility, and pregnancy. Endocrinol Metab Clin North Am 2026;55:637-648. doi:10.1016/j.ecl.2026.07.003
    5. MOUNJARO (tirzepatide) prescribing information. Eli Lilly and Company; label text as published by the U.S. Food and Drug Administration, July 2026; section 7.2. dailymed.nlm.nih.gov
    6. Oral contraception and GLP-1 agonists. Drug Ther Bull 2025;64:8; overview of the Faculty of Sexual and Reproductive Healthcare statement of February 2025. doi:10.1136/dtb.2025.000049
    7. Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. Guidance, updated 5 February 2026. gov.uk
    8. Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med 2024;184:144-152. doi:10.1001/jamainternmed.2023.6663

    Related analyses

    Log your doses and the app marks each backup window.

    Open Dose Insider